PD 123319
Based on 11 publication(s) in Google Scholar
PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 130663-39-7
- 화학식: C31H32N4O3
- 분자량:508.61
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PD 123319
More- Redox Biol. 2021 Oct:46:102115 [Abstract]
- J Exp Med. 2022 Mar 7;219(3):e20211001. [Abstract]
- Acta Pharmacol Sin. 2024 Jun;45(6):1201-1213. [Abstract]
- Clin Transl Med. 2025 Jun;15(6):e70361. [Abstract]
- Acta Physiol. 2026 Apr;242(4):e70200. [Abstract]
- Int Immunopharmacol. 2022 Sep:110:108921. [Abstract]
- FASEB J. 2019 May;33(5):6254-6268. [Abstract]
- FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
- Neurosci Lett. 2025 Aug 28:138369. [Abstract]
- Rep Biochem Mol Biol. 2021 Jul;10(2):314-326. [Abstract]
- SSRN. 13 Apr 2022.
Customer Validation & Images
-
WB
All Angiotensin Receptor Isoforms
More
Biological Activity
|
AT2 Receptor |
PD 123319 is shown to discriminate between two subclasses of AII receptors in many different tissues. 125I-AII specifically label two classes of binding sites for AII in a membrane preparation of bovine adrenal glomerulosa cells. The first class (DuP-753 sensitive) represents approximately 85% of the total binding sites for AII and possesses a high affinity (IC50 of 92.9 nM) for DuP-753. PD-123319 does not have any effect on 125I-AII binding to this site. The second class of binding sites is more sensitive to PD-123319, with an IC50 of 6.9 nM, and has a much lower affinity for DuP-753 (IC50 around 10 microM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 130663-39-7
-
분자량 508.61
-
화학식 C31H32N4O3
-
SMILES
O=C([C@@H]1CC2=C(N=CN2CC3=CC=C(N(C)C)C(C)=C3)CN1C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)O
-
Synonyms
(S)-(+)-PD 123319
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension. [Abstract]2021 Oct:46:102115 PMID: 34474396 -
J Exp Med
Angiotensin II enhances group 2 innate lymphoid cell responses via AT1a during airway inflammation. [Abstract]2022 Mar 7;219(3):e20211001. PMID: 35044462 -
Acta Pharmacol Sin
Angiotensin II type-2 receptor signaling facilitates liver injury repair and regeneration via inactivation of Hippo pathway. [Abstract]2024 Jun;45(6):1201-1213. PMID: 38491160 -
Clin Transl Med
DDR2-mediated autophagy inhibition contributes to angiotensin II-induced adventitial remodeling. [Abstract]2025 Jun;15(6):e70361. PMID: 40468620 -
Acta Physiol
Angiotensin-(1-7) Alleviates Isoproterenol-Induced Cardiac Hypertrophy by Suppressing Autophagy and Apoptosis Through the Synergistic Action of Mas Receptor and Angiotensin II Type 2 Receptor. [Abstract]2026 Apr;242(4):e70200. PMID: 41886752 -
Int Immunopharmacol
Angiotensin II type 2 receptor pharmacological agonist, C21, reduces the inflammation and pain hypersensitivity in mice with joint inflammatory pain. [Abstract]2022 Sep:110:108921. PMID: 35724606 -
FASEB J
Transactivation domain of Krüppel-like factor 15 negatively regulates angiotensin II-induced adventitial inflammation and fibrosis. [Abstract]2019 May;33(5):6254-6268. PMID: 30776250 -
FASEB J
Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1. [Abstract]2018 Sep;32(9):5051-5062. PMID: 29641288
PD 123319 purchased from MedChemExpress. Usage Cited in: FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
HUVECs are starved for 12 h, treated with 10 mg/mL (9.56 μM) of AngII with or without Losartan or PD123319 for 12 h, and are subsequently used for Western blot analysis.
-
Neurosci Lett
A novel angiotensin II type 2 receptor antagonist TDI05 alleviates the peripheral neuropathic pain. [Abstract]2025 Aug 28:138369. PMID: 40885515 -
Rep Biochem Mol Biol
Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes. [Abstract]2021 Jul;10(2):314-326. PMID: 34604421 -
Protocol
The lower limit of CBF autoregulation is studied in 16 SHR. Eight animals receive PD 123319, while eight serve as controls. PD 123319 or saline is administered intravenously, and the BP is allowed to stabilise for 10 minutes after the injection and prior to the commencement of the autoregulation study. Haemorrhagic hypotension is subsequently induced by withdrawing blood into a syringe. By this means, BP is reduced stepwise to the lowest obtainable level. Throughout the study, CBF is measured at 10 to 15 mmHg BP intervals.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
순도&문서
References
[1]. Blankley CJ, et al. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem. 1991 Nov;34(11):3248-60. [Content Brief]
[2]. Boulay G, et al. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa. Mol Pharmacol. 1992 Apr;41(4):809-15 [Content Brief]
[3]. Estrup TM, et al. No effect of angiotensin II AT(2)-receptor antagonist PD 123319 on cerebral blood flow autoregulation. J Renin Angiotensin Aldosterone Syst. 2001 Sep;2(3):188-92. [Content Brief]
[4]. Brillante DG, et al. Effects of intravenous PD 123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin Angiotensin Aldosterone Syst. 2005 Sep;6(2):102-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PD 123319 Related Classifications
HY-10259 Related Classifications
Powered by Bioz